NervGen Pharma Corp. NGEN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 216.48% | 55.60% | -213.86% | 24.76% | -14.45% |
| Total Depreciation and Amortization | 0.00% | 5.15% | -11.50% | -5.61% | -8.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -437.66% | -809.81% | 395.84% | -540.69% | 41.01% |
| Change in Net Operating Assets | -202.81% | -641.99% | -126.03% | 40.22% | 88.84% |
| Cash from Operations | -56.35% | -108.29% | -75.52% | 8.47% | 13.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -65.34% | 0.56% | -1.08% | 198.36% |
| Cash from Investing | -100.00% | -65.34% | 0.56% | -1.08% | 198.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 66.67% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 1,605.41% | 61.30% | 4,963.99% | 273.22% | 2,901.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,910.44% | 89.03% | -- | -- | -427.74% |
| Cash from Financing | 1,543.69% | 128.19% | 5,321.67% | 265.32% | 4,124.97% |
| Foreign Exchange rate Adjustments | -2,508.09% | -554.09% | 181.03% | 86.30% | -71.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5,734.22% | -106.18% | 387.36% | 23.11% | 131.79% |